Metabolic changes in the lower esophageal sphincter influencing the result of anti-reflux surgical interventions in chronic gastroesophageal reflux disease

Table 2 Lysosomal enzyme activities in normal LES and in LES operated due to gastroesophageal reflux, as well as in patients with and without complaints in the postoperative period.

Enzymes	LES				P	LES in GERD				P
	Normal		GERD			Visick I		Visick II–III
	Mean	SE	Mean	SE	Mean	SE	Mean	SE
CB	14177.5	3441.9	7727.6	1913.9	P<0.001	6442.8	2242.7	10439.8	3548.1	P<0.05
TPP I	74318.0	10742.6	47509.9	5339.3	P<0.001	47541.6	6760.4	47438.5	11067.2	NS
DPP II	3970.4	1189.3	2513.3	512	P<0.001	2860.7	647.1	1779.7	744.1	P<0.05
HEX	17253.7	4457.9	9185.0	1604.7	P<0.001	9528.2	2267.2	8460.4	2054.9	NS
GCU	17345.0	5145.4	13123.5	2307.5	NS	13980.1	3263.8	11315.2	2541.3	NS
BMAN	4207.5	1246.1	2922.9	587.7	P<0.05	3248.4	824.1	2235.9	481.4	NS
AMAN	962.4	726.8	469.9	172.2	NS	567.4	232.8	238.5	108.9	NS
BGAL	17714.3	3561.0	11396.7	1567.3	P<0.001	11733.9	2241.9	10684.9	1821.4	NS

LES: lower esophageal sphincter; GERD: gastroesophageal reflux disease; Visick I: symptom-free; Visick II–III: mild symptoms can be treated with medication; SE: standard error; P: significance; NS: non-significant; CB: cathepsin B; TPP I: tripeptidyl-peptidase I; DPP II: dipeptidyl-peptidase II; HEX: β-hexosaminidase B; GCU: β-glucuronidase; BMAN = β-mannosidase; AMAN: α-mannosidase; BGAL: β-galactosidase (pmoL/h·mg).